60.03USD-2.37%Mkt Cap: 5.29B USDP/E: —Last update: 2026-06-01
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cre…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.29B USD
Enterprise Value4.43B USD
Revenue (TTM)5.07M USD
Gross Profit-607.00K USD
Net Income (TTM)-161.00M USD
Revenue/Share0.0640 USD
Last Price60.03 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees142
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.41
PEG—
EV/EBITDA-20.81
EV/Revenue872.70
P/S1083.44
P/B5.02
EPS (TTM)-2.34
EPS (Forward)-2.78
52W Range
23.6570% of range75.50
52W High75.50 USD
52W Low23.65 USD
Profitability
Gross Margin-15.02%
Oper. Margin-6130.10%
EBITDA Margin0.00%
Profit Margin-3985.02%
ROE-21.39%
ROA-20.34%
Growth
Revenue Growth1982.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-132.35M USD
CapEx (TTM)134.00K USD
FCF Margin-2088.16%
FCF Yield-2.00%
Net Debt-1.07B USD
Net Debt/EBITDA5.02
Balance Sheet
Debt/Equity0.01
Current Ratio31.30
Quick Ratio30.60
Book Value/Sh12.40 USD
Cash/Share12.20 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)90.29 USD
Target Range80.00 USD – 108.00 USD
# Analysts14
Ownership
Shares Out.88.20M
Float65.82M
Insiders0.23%
Institutions110.21%
Short Interest
Short Ratio9.8d
Short % Float10.59%
Short % Out.10.41%
Shares Short9.18M
Short (prev mo.)9.53M
Technical
SMA 5066.99 (-10.4%)
SMA 20049.51 (+21.2%)
Beta0.42
S&P 52W Chg27.94%
Avg Vol (30d)831.52K
Avg Vol (10d)1.00M
Technical Indicators
RSI (14)39.1
MACD-1.6124
MACD Signal-0.7918
MACD Hist.-0.8206
BB Upper73.77 USD
BB Middle66.24 USD
BB Lower58.71 USD
BB Width22.73%
ATR (14)2.980 USD
Vol Ratio (20d)0.55x